Search Results 291-300 of 16103 for SC

  1. Publications - Rick J. Bold, M.D., M.B.A. - Mayo Clinic

    ... SC, Kim KK. The Personal Health Network Mobile App for Chemotherapy Care Coordination: Qualitative Evaluation of a Randomized Clinical Trial. JMIR Mhealth ...

  2. Vasculitis Clinical Trials - Mayo Clinic Research

    The aim of this study is to investigate the effectiveness and safety of depemokimab 200 mg (administered as 100 mg x 2) SC injections every 26 weeks compared ...

  3. Ovarian Cancer Clinical Trials - Mayo Clinic Research

    SC-003 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. Vaccine Therapy Plus Pembrolizumab in Treating ...

  4. Lupus - Symptoms & causes - Mayo Clinic

    This is called an autoimmune condition. Lupus causes swelling and irritation, called inflammation, that may affect joints, skin, kidneys, blood cells, brain, ...

  5. Alumni - Bone and Soft Tissue Pathology Fellowship (Minnesota) - Mayo Clinic College of Medicine & Science

    Great Lakes Pathologist S.C., West Allis, WI. 2021, Judith Jebastin Thangaiah, M.B.B.S., Mayo Clinic, Rochester, MN. 2020, Nicholas Olson, M.D., Physicians ...

  6. Publications - Samir H. Patel, M.D. - Mayo Clinic

    ... SC, Gamez ME, Rwigema JM, Holtzman AL, Price DL, Janus JR, Kasperbauer JL ... SC, Ma DJ, McGee LA, Moore EJ, Neben Wittich MA, Patel SH, Routman DM ...

  7. Clinical trials - Oncology (Medical)

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  8. Contact us - Mayo Clinic

    SC: Mayo Clinic Breadcrumb. About Mayo Clinic · Mayo Clinic Care Network. Sections Mayo Clinic Care Network. Amplify expertise. Collapse Amplify expertise.

  9. Publications - John V. Murray, Jr., M.D. - Mayo Clinic

    Epub 2023 Apr 07. View PubMed; Philip JT, Flores MA, Beegle RD, Dodson SC, Messina SA, Murray JV Jr. Reply. AJNR Am J Neuroradiol 2023 Feb; 44 (2):E12 Epub ...

  10. A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease - Mayo Clinic

    The purpose of this study is to assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely ...